MIRA INFORM REPORT

 

 

Report Date :           

24.04.2012

 

IDENTIFICATION DETAILS

 

Name :

P.T. CAPSUGEL INDONESIA

 

 

Registered Office :

Jalan Raya Bogor Km. 42, Cibinong 16916, West Java

 

 

Country :

Indonesia

 

 

Date of Incorporation :

14.02.1996

 

 

Com. Reg. No.:

No. AHU-56152.AH.01.02.Tahun 2011

 

 

Legal Form :

Limited Liability Company

 

 

Line of Business :

Gelatin Capsule Manufacturing 

 

 

No. of Employees :

155 persons (permanent)

160 persons (non permanent)            

 

RATING & COMMENTS

 

MIRA’s Rating :

Ba

 

RATING

STATUS

PROPOSED CREDIT LINE

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

Satisfactory

 

Maximum Credit Limit :

US$ 4.9 million

Status :

Good

Payment Behaviour :

No Complaints

Litigation :

Clear


 

NOTES:

Any query related to this report can be made on e-mail : infodept@mirainform.com while quoting report number, name and date.

 

ECGC Country Risk Classification List – March 31st, 2012

 

Country Name

Previous Rating

                   (31.12.2011)                  

Current Rating

(31.03.2012)

Indonesia

b1

b1

 

Risk Category

ECGC Classification

Insignificant

 

A1

Low

 

A2

Moderate

 

B1

High

 

B2

Very High

 

C1

Restricted

 

C2

Off-credit

 

D

 


Name of Company

 

P.T. CAPSUGEL INDONESIA

 

 

company Address

 

Head Office & Factory

Jalan Raya Bogor Km. 42

Cibinong 16916

West Java

Indonesia

Phone               - (62-21) 875 2226 (Hunting)

Fax.     - (62-21) 875 2227

P.O. Box           - 15/CBI

Email                - Indonesia_CS@capsugel.com

Land Area         - 9,300 sq. meters

Factory Space   - 7,600 sq. meters

Region              - Industrial Zone

Status               - Owned

 

 

Date of Incorporation

 

14 February 1996

 

 

Legal Form

 

P.T. (Perseroan Terbatas) or Limited Liability Company

 

           

Company Reg.No.

 

The Ministry of Law and Human Rights

a. No. C-30274 HT.01.04.TH.2003

    Dated 31 December 2003

b. No. AHU-29540.AH.01.02.Tahun 2010

    Dated 10 June 2010

c. No. AHU-56152.AH.01.02.Tahun 2011

    Dated 17 November 2011

 


Company Status 

 

Foreign Investment Company (PMA)

 

           

Permit by the Government Department

 

The Capital Investment Coordinating Board 

- No. 144/I/PMA/1996

  Dated 12 February 1996

- No. 1646/III/PMA/1998

  Dated 19 November 1998

 

- No. 02/II/PMA/2000

  Dated 6 June 2000

- No. 231/II/PMA/2002

  Dated 30 October 2002

 

The Department of Finance

NPWP No. 01.071.413.7-052.000

 

 

Related Companies

 

a. WARNER LAMBERT COMPANY LLC., of the USA (Investment Holding)

b. INTERNATIONAL AFFILIATED Corp., LLC., of the USA (Investment Holding)

 

 

CAPITAL AND OWNERSHIP

 

Capital Structure :

Authorized Capital             - US$ 21,500,000.- (Rp. 136,325,000,000)

Issued Capital                   - US$ 21,500,000.- (Rp. 136,325,000,000)

Paid up Capital                 - US$ 21,500,000.- (Rp. 136,325,000,000)

 

Shareholders/Owners :

a. CAPSUGEL BELGIUM BVBA                         - US$ 21,285,000.- (99%)

   Address : 2880 Bornem, Rijksweg11

                   Brussels

                   Belgium

b. CAPSUGEL FINANCECO II S.A.R.L.              - US$      215,000.- (  1%)

   Address : 63, Ru De Rollingergrund,

                   L-2440 Luxembourg

                   Luxembourg

 

BUSINESS ACTIVITIES                           

 

Lines of Business :

Gelatin Capsule Manufacturing 

 

Production Capacity :

a. Gelatin Capsules                    - 4,600 million pcs. p.a.

b. Trading and Import Services    - US$ 2.0 million

 

Total Investment :

a. Equity Capital                        - US$ 21.5 million

b. Reinvested Profit                    - US$   1.5 million

c. Loan Capital                          - US$ 10.2 million

d. Total Investment                     - US$ 33.2 million

 

Started Operation :

1996

 

Brand Name :

Capsugel Gelatin Capsule

 

Technical Assistance :

CAPSUGEL BELGIUM BVBA of Belgium

 

Number of Employee :

a. 155 persons (permanent)

b. 160 persons (non permanent)         

 

Marketing Area :

Domestic          - 60%

Export               - 40%   

 

Main Customers :

a. P.T. SANBE FARMA

b. P.T. DEXA MEDICA

c. P.T. FERRON FARMA

d. P.T. INDO FARMA

e. About 35% of the products are exported to several Asian countries

 

Market Situation :

Very Competitive

 

Main Competitors :

a. P.T. KAPSULINDO NUSANTARA

b. P.T. UNIVERSAL PHARMACEUTICAL INDUSTRY

c. P.T. DANKOS LABORATORIES

d. P.T. KALBE FARMA Tbk

e. P.T. KIMIA FARMA Tbk

f.  P.T. PHAROS INDONESIA Tbk

g. Etc.

 

Business Trend :

Growing

 

 

BANKER, AUDITOR & LITIGATION

 

Bankers :

a. CITIBANK N.A.

    Landmark Center

    Jalan Jend. Sudirman No. 1

    Jakarta Pusat

    Indonesia

b. AMERICAN EXPRESS Bank

    American Express Bank Building

    Jalan H.R. Rasuna Said Block X-1

    Jakarta Selatan

    Indonesia

 

Auditor :

Internal Auditor

 

Litigation :

No litigation record in our database

 

 

FINANCIAL FIGURE

 

Annual Sales (estimated) :

2008 – Rp. 232.0 billion

2009 – Rp. 268.0 billion

2010 – Rp. 310.0 billion

2011 – Rp. 358.0 billion

 

Net Profit (estimated) :

2008 – Rp. 14.0 billion

2009 – Rp. 16.2 billion

2010 – Rp. 18.7 billion

2011 – Rp. 21.5 billion

 

Payment Manner :

Average

 

Financial Comments :

Satisfactory


KEY EXECUTIVES

 

Board of Management :

President Director                      - Mr. Eddy Suyadi

Directors                                   - a. Mr. Muhammad Said Bernad Hananto

  b. Mr. Vanchai Santimonachai

 

Board of Commissioners :

Commissioner                           - Mr. Guido Edouard Driesen

 

Signatories :

President Director (Mr. Eddy Suyadi) or one of the Directors (Mr. Muhammad Said Bernad Hananto and Mr. Vanchai Santimonachai) which must be approved by the Board of Commissioners

 

 

CAPABILITIES

 

Management Capability :

Good

 

Business Morality :

Good

 

Credit Risk :

Below Average

 

Credit Recommendation :

Credit should be proceeded normally

 

Proposed Credit Limit :

Moderate amount

 

Maximum Credit Limit :

US$ 4.9 million on the 90 days of payments

 

 

OVERALL PERFORMANCE

 

P.T. CAPSUGEL INDONESIA (P.T. CI) was established in February 1996 with the authorized capital of US$ 3,500,000 wholly issued and paid up. The founding shareholders of the company are WARNER LAMBERT COMPANY and INTERNATIONAL AFFILIATED CORPORATION, both of the USA. The articles of association of the company have frequently been revised.   In December 1998, the authorized capital of the company was raised to US$ 7,500,000 (Rp 17,325,000,000) wholly issued and paid up. The deed of amendment was made by Mr. Singgih Susilo, SH., a public notary in Jakarta under Company Registration Number C-30274HT.01.04.TH.2003, dated 31 December 2003 and No. C-UM.02.01.6601, dated 26 April 2006.  On April 2010, Mr. Charles Robert Danjut, Mrs. Sapti Damajanti and Mr. Thomas Dharmasaputra withdraw and their position was replaced by Vanchai Santimonachai, Mr. Luthfi Mardiansyah, Mr. Lukman Hidayat and Mrs. Bhanuwati Citarasmi. The deed of amendment was made by Ms. Irene Yulia, SH., a public notary in Jakarta under Company Registration Number AHU-29540.AH.01.02.Tahun 2010 dated 10 June 2010.

 

Latest, on November 2011, the authorized capital was raised to US$ 21,500,000 (Rp. 136,325,000,000) entirely was issued and fully paid up.  Since the time, the shareholders of the company are CAPSUGEL BELGIUM BVBA of Belgium (99%) and CAPSUGEL FINANCECO II S.A.R.L., of Luxembourg (1%).   The deed of amendment was made by Ms. Mala Mukti, SH., a public notary in Jakarta under Company Registration Number AHU-56152.AH.01.02.Tahun 2011 dated 17 November 2011.  No changes have been effected in term of its shareholding composition and capital structures to date.

 

P.T. CI obtained a Foreign Capital Investment (PMA) facility issued by the Capital Investment Coordinating Board (BKPM) to deal with Gelatin Capsule industry having been in operation since 1996 by taking over the activities and assets of P.T. GELATINDO MUKTI GRAHA having been in operation since 1984. Its plant is located at Jalan Raya Bogor Km. 42, Cibinong, West Java on a land of 9,300 square meters having frequently been revised. The plant has been expansion frequently to increasing production capacity in gelatin capsules of 4,600 million pcs per annum. Some 65% of the products are locally marketed among pharmaceutical industries such as P.T. SANBE FARMA, P.T. DEXA MEDICA, P.T. FERRON FARMA, P.T. INDOFARMA and others.  Meanwhile, the rest 35% of this is exported to several Asian countries.  We observe that P.T. CI is classified as the largest sized company of its kind in the country of which the operation has been growing in the last three years.

 

Generally, the demand for gelatin capsules or empty capsules in the country had significantly rising by 8% to 10% per year in the last five years, in line with the growth of pharmaceutical industries as pictured in sales value of national pharmaceutical products, import value and export value issued by the Food and Drug Controlling Board (BPOM). The national pharmaceutical sales, export and import value of products are estimated to be rising by 6% to 8% in the next year. The competition is very tight on account many similar companies operating in the country such as P.T. KAPSULINDO NUSANTARA, P.T. UNIVERSAL PHARMACEUTICAL INDUSTRY, P.T. DANKOS LABORATORIES and others.  It is estimated that the demand for gelatin capsules would be rising by 6% per annum. The business position of P.T. CI is favorable because its merchandise products have already been popular in the country.

 

Until this time P.T. CI has not been registered with Indonesian Stock Exchange, so that they shall not obliged to announce their financial statement. We observed that total sales turnover of the company in 2009 amounted to Rp. 268.0 billion increased to Rp. 310.0 billion in 2010 and rose again to Rp. 358.0 billion in 2011.  The operation in 2009 yielded an estimated net profit at least Rp. 16.2 billion rose to Rp. 18.7 billion in 2010 and rose again to Rp. 21.5 billion in 2011.  The company has an estimated total net worth at Rp. 160.0 billion.  It is projected that total sales turnover of the company will increase at least 8% in 2012. We observe that P.T. CI is supported by financially strong foreign partners behind it. So far, we have never heard of the company having been black listed by the Central Bank (Bank Indonesia). The company usually pays its debts punctually to suppliers.  

 

The management of P.T. CI is led by Mr. Eddy Suyadi (50) with 17 years of experience in the gelatine capsules manufacturing and trade.  Daily activities, he is assisted by four directors namely Mr. Muhammad Said Bernad (45) and Mr. Vonchai Santimonachai (57) from Thailand.  The management of the company is also handled by professional managers having wide relation with private businessmen within and outside the country and with the government sectors as well.  We observed that management’s reputation in said business is fairly good.  So far, we have never heard that the company’s management involved in a dirty business practice or detrimental cases that settled in the country. The company’s litigation record is clean and it has not registered with the black list of Bank of Indonesia.

 

PT. CAPSUGEL INDONESIA is fairly good for business transaction. However, in view of the unstable economic condition in the country we recommend to treat prudently in extending a loan to the company.

 


 

FOREIGN EXCHANGE RATES

 

Currency

Unit

Indian Rupees

US Dollar

1

Rs.52.23

UK Pound

1

Rs.84.16

Euro

1

Rs.68.84

 

 

RATING EXPLANATIONS

 

RATING

STATUS

 

 

PROPOSED CREDIT LINE

>86

Aaa

Possesses an extremely sound financial base with the strongest capability for timely payment of interest and principal sums

 

Unlimited

71-85

Aa

Possesses adequate working capital. No caution needed for credit transaction. It has above average (strong) capability for payment of interest and principal sums

 

Large

56-70

A

Financial & operational base are regarded healthy. General unfavourable factors will not cause fatal effect. Satisfactory capability for payment of interest and principal sums

 

Fairly Large

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

 

Satisfactory

26-40

B

Capability to overcome financial difficulties seems comparatively below average.

 

Small

11-25

Ca

Adverse factors are apparent. Repayment of interest and principal sums in default or expected to be in default upon maturity

 

Limited with full security

<10

C

Absolute credit risk exists. Caution needed to be exercised

 

 

Credit not recommended

----

NB

New Business

----

 

This score serves as a reference to assess SC’s credit risk and to set the amount of credit to be extended. It is calculated from a composite of weighted scores obtained from each of the major sections of this report. The assessed factors and their relative weights (as indicated through %) are as follows:

 

Financial condition (40%)            Ownership background (20%)                  Payment record (10%)

Credit history (10%)                   Market trend (10%)                                Operational size (10%)

 

 

 

PRIVATE & CONFIDENTIAL : This information is provided to you at your request, you having employed MIPL for such purpose. You will use the information as aid only in determining the propriety of giving credit and generally as an aid to your business and for no other purpose. You will hold the information in strict confidence, and shall not reveal it or make it known to the subject persons, firms or corporations or to any other. MIPL does not warrant the correctness of the information as you hold it free of any liability whatsoever. You will be liable to and indemnify MIPL for any loss, damage or expense, occasioned by your breach or non observance of any one, or more of these conditions

This report is issued at your request without any risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL) or its officials.